Compugen Ltd (CGEN) 8.34 $CGEN
CORRECTED DATE FOR Q2 CONFERENCE CALL: Compugen Second Quarter 2014 Conference Call Scheduled for Wednesday, August 6, 2014 at 10:00 AM EDT
Business Wire - Thu Jul 31, 6:37AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Wednesday, August 6, 2014 to review the second quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com), prior to the conference call. A previous release stating August 5 as the date for the call was in error.
Compugen Has Returned 16.1% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Wed Jul 30, 4:57PM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 4 months, Compugen has returned 16.06% as of today's recent price of $8.70.
Compugen Second Quarter 2014 Conference Call Scheduled for Tuesday, August 5, 2014 at 10:00 AM EDT
Business Wire - Tue Jul 29, 6:01AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Tuesday, August 5, 2014 to review the second quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com), prior to the conference call.
Compugen to Present Immune Checkpoint Related Research at Two Scientific Conferences
Business Wire - Thu Jul 24, 6:02AM CDT
--Results for CGEN-15001 fusion protein based on checkpoint protein candidate to be presented at International Conference on Immune Tolerance in Amsterdam
Compugen Down 15.6% Since SmarTrend Downtrend Call (CGEN)
Comtex SmarTrend(R) - Wed Jul 23, 11:11AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 4 months, Compugen has returned 15.58% as of today's recent price of $8.75.
Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins
Business Wire - Mon Jul 14, 6:00AM CDT
--New candidates enter Company's Pipeline Program
Shares of CGEN Down 16.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Jul 09, 9:13AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 4 months, Compugen has returned 16.35% as of today's recent price of $8.67.
Analysis of Global Biochips Industry, 2012-2018
M2 - Wed Jul 09, 2:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf67jr/analysis_of) has announced the addition of the "Analysis of Global Biochips Industry, 2012-2018" report to their offering. Global biochips market is forecasted to reach US$11.4 billion by 2018 with a CAGR of 18.6% during 2012-2018; the massive CAGR is primarily supported by Asia-Pacific followed by the European Union. Among the major industry segments, biochips instruments are expected to exert the highest support to the industry with a CAGR of 20% globally. Microarrays segment accounts for nearly 70% of the industry value while services indicate lesser than 15% of the market value. North America is expected to maintain the highest market share for the biochips industry by 2018; Asian economies are expected to post a large CAGR of 19 percent during 2012-2018. Higher growth rate favors improved industry investments in Asia-Pacific region in comparison with North America and Europe, going ahead. Report Focus: The report Analysis of Global Biochips Industry, 2012-2018' reviews the latest biochips market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for life science sector investments. The study reveals profitable investment strategies for pharmaceutical manufacturers, biotechnology companies, laboratories, Contract Research Organizations (CROs), government organizations and many more in preferred locations. The report primarily focuses on: Companies Mentioned: - Affymetrix, Inc. - Agilent Technologies - Arkray, Inc. - Biobase - Biodot, Inc. - Biofluidix Gmbh - Biom?rieux Sa - Cellix Limited - Compugen - Courtagen Life Sciences, Inc. - Cytopathfinder, Inc. - Dr. Chip Biotechnology Inc. - Epigem Ltd. - Immunexpress Pty Ltd - Lavision Biotec Gmbh - Lightarray Gene Technology Co., Ltd. - Med Biogene Inc. - Microarrays, Inc. - Micronit Microfluidics Bv - Miltenyi Biotec - Mitsubishi Rayon Co., Ltd. - Nanosphere, Inc. - Nanostring? Technologies, Inc. - Promega Corporation - Protagen Ag - Strand Life Sciences - Ttp Labtech Ltd - Vance Street Capital Llc - Varionostic Gmbh - Zeptosens Ag For more information visit http://www.researchandmarkets.com/research/zf...nalysis_of
Compugen Discloses Achievement of Milestone in Cancer Immunotherapy Collaboration with Bayer
Business Wire - Mon Jul 07, 6:11AM CDT
Compugen Ltd. (NASDAQ: CGEN) disclosed today that it has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer). The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen. The milestone being announced today relates to the first preclinical milestone for one of two checkpoint protein candidates for which Compugen will receive a $1.2 million payment out of the $30 million potential milestone payments associated with joint preclinical research for the two programs.
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Compugen and SRG Security Resource Group Inc. (SRG) to Collaborate in Western Canada
Marketwire - Tue Jun 24, 10:01AM CDT
Compugen and SRG Security Resource Group Inc. (SRG) announced today their plans to enter into an agreement whereby SRG will provide a comprehensive set of Managed Security Services to Compugen clients in Western Canada.
Compugen Shares Down 13.7% Since SmarTrend's Sell Call (CGEN)
Comtex SmarTrend(R) - Fri Jun 20, 5:09PM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 3 months, Compugen has returned 13.65% as of today's recent price of $8.95.
Will Compugen (CGEN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 7:37AM CDT
Will Compugen (CGEN) Continue to Surge Higher?
Nasdaq stocks posting largest percentage increases
AP - Tue Jun 17, 12:27PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Why Compugen Ltd. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Mon Jun 16, 2:10PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Compugen , a clinical-stage...
Compugen and Spyders Collaborate to Provide Managed Security Services in Eastern Canada
Marketwire - Mon Jun 16, 10:01AM CDT
Compugen and Spyders announced today their plans to enter into an agreement whereby Spyders will provide a comprehensive set of Managed Security Services to Compugen clients in Eastern Canada.
CORRECTED DATE FOR Q2 CONFERENCE CALL: Compugen Second Quarter 2014 Conference Call Scheduled for Wednesday, August 6, 2014 at 10:00 AM EDT
Business Wire - Thu Jul 31, 6:37AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Wednesday, August 6, 2014 to review the second quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com), prior to the conference call. A previous release stating August 5 as the date for the call was in error.
Compugen Has Returned 16.1% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Wed Jul 30, 4:57PM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 4 months, Compugen has returned 16.06% as of today's recent price of $8.70.
Compugen Second Quarter 2014 Conference Call Scheduled for Tuesday, August 5, 2014 at 10:00 AM EDT
Business Wire - Tue Jul 29, 6:01AM CDT
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Tuesday, August 5, 2014 to review the second quarter 2014 results. The quarterly results will be released on the Company's website (www.cgen.com), prior to the conference call.
Compugen to Present Immune Checkpoint Related Research at Two Scientific Conferences
Business Wire - Thu Jul 24, 6:02AM CDT
--Results for CGEN-15001 fusion protein based on checkpoint protein candidate to be presented at International Conference on Immune Tolerance in Amsterdam
Compugen Down 15.6% Since SmarTrend Downtrend Call (CGEN)
Comtex SmarTrend(R) - Wed Jul 23, 11:11AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 4 months, Compugen has returned 15.58% as of today's recent price of $8.75.
Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins
Business Wire - Mon Jul 14, 6:00AM CDT
--New candidates enter Company's Pipeline Program
Shares of CGEN Down 16.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Jul 09, 9:13AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 4 months, Compugen has returned 16.35% as of today's recent price of $8.67.
Analysis of Global Biochips Industry, 2012-2018
M2 - Wed Jul 09, 2:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf67jr/analysis_of) has announced the addition of the "Analysis of Global Biochips Industry, 2012-2018" report to their offering. Global biochips market is forecasted to reach US$11.4 billion by 2018 with a CAGR of 18.6% during 2012-2018; the massive CAGR is primarily supported by Asia-Pacific followed by the European Union. Among the major industry segments, biochips instruments are expected to exert the highest support to the industry with a CAGR of 20% globally. Microarrays segment accounts for nearly 70% of the industry value while services indicate lesser than 15% of the market value. North America is expected to maintain the highest market share for the biochips industry by 2018; Asian economies are expected to post a large CAGR of 19 percent during 2012-2018. Higher growth rate favors improved industry investments in Asia-Pacific region in comparison with North America and Europe, going ahead. Report Focus: The report Analysis of Global Biochips Industry, 2012-2018' reviews the latest biochips market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for life science sector investments. The study reveals profitable investment strategies for pharmaceutical manufacturers, biotechnology companies, laboratories, Contract Research Organizations (CROs), government organizations and many more in preferred locations. The report primarily focuses on: Companies Mentioned: - Affymetrix, Inc. - Agilent Technologies - Arkray, Inc. - Biobase - Biodot, Inc. - Biofluidix Gmbh - Biom?rieux Sa - Cellix Limited - Compugen - Courtagen Life Sciences, Inc. - Cytopathfinder, Inc. - Dr. Chip Biotechnology Inc. - Epigem Ltd. - Immunexpress Pty Ltd - Lavision Biotec Gmbh - Lightarray Gene Technology Co., Ltd. - Med Biogene Inc. - Microarrays, Inc. - Micronit Microfluidics Bv - Miltenyi Biotec - Mitsubishi Rayon Co., Ltd. - Nanosphere, Inc. - Nanostring? Technologies, Inc. - Promega Corporation - Protagen Ag - Strand Life Sciences - Ttp Labtech Ltd - Vance Street Capital Llc - Varionostic Gmbh - Zeptosens Ag For more information visit http://www.researchandmarkets.com/research/zf...nalysis_of
Compugen Discloses Achievement of Milestone in Cancer Immunotherapy Collaboration with Bayer
Business Wire - Mon Jul 07, 6:11AM CDT
Compugen Ltd. (NASDAQ: CGEN) disclosed today that it has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer). The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen. The milestone being announced today relates to the first preclinical milestone for one of two checkpoint protein candidates for which Compugen will receive a $1.2 million payment out of the $30 million potential milestone payments associated with joint preclinical research for the two programs.
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Compugen and SRG Security Resource Group Inc. (SRG) to Collaborate in Western Canada
Marketwire - Tue Jun 24, 10:01AM CDT
Compugen and SRG Security Resource Group Inc. (SRG) announced today their plans to enter into an agreement whereby SRG will provide a comprehensive set of Managed Security Services to Compugen clients in Western Canada.
Compugen Shares Down 13.7% Since SmarTrend's Sell Call (CGEN)
Comtex SmarTrend(R) - Fri Jun 20, 5:09PM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 3 months, Compugen has returned 13.65% as of today's recent price of $8.95.
Will Compugen (CGEN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 7:37AM CDT
Will Compugen (CGEN) Continue to Surge Higher?
Nasdaq stocks posting largest percentage increases
AP - Tue Jun 17, 12:27PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Why Compugen Ltd. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Mon Jun 16, 2:10PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Compugen , a clinical-stage...
Compugen and Spyders Collaborate to Provide Managed Security Services in Eastern Canada
Marketwire - Mon Jun 16, 10:01AM CDT
Compugen and Spyders announced today their plans to enter into an agreement whereby Spyders will provide a comprehensive set of Managed Security Services to Compugen clients in Eastern Canada.
